Investegate |T-knife Therapeutics Announcements | T-knife Therapeutics: T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Related Keywords

Berlin ,Germany ,Max Delbr ,Thomasm Soloway ,Camille Landis ,Therapeutics Inc ,Globe Newswire Therapeutics Inc , ,T Knife Therapeutics Announces Dosing ,First Patient ,Melanoma Associated Antigen Gene A ,Myt Platform ,Eugen Leo ,Chief Medical Officer ,Chief Executive Officer ,T Knife Myt ,Molecular Medicine ,Business Officer ,Chief Financial ,Investegate Announcements ,Investegate Company Announcements ,T Knife Therapeutics ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,